** Cancer drug developer Arcus Biosciences Inc's  RCUS.N 
early-stage data of pancreatic cancer treatment exceeded
expectations, says Truist analyst Robyn Karnauskas
    ** Truist raises PT to $70 from $45; adds data from study
further validates RCUS' combo strategy across different
indications
    ** RCUS said on Friday its combination therapy, AB680, to
treat pancreatic cancer showed 41% objective response rate in an
early-stage trial. Data from trial was from 17 patients
    ** With multiple catalysts in 2021, we see potential for
significant upside to stock - Robyn Karnauskas
    ** Adds data support Gilead Inc's  GILD.O  partnership
strategy
    ** RCUS and GILD entered into 10-year partnership to
co-develop and co-commercialize RCUS's pipeline in May 2020
 urn:newsml:reuters.com:*:nL4N2D92II
    ** 9 of 10 brokerages rate stock "buy" or higher, 1 "hold";
their median PT is $40
    ** Stock has more than tripled in last 12 months 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))